Newer antifungal agents

References

• Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J. Antimicrob. Chemother.61(Suppl. 1), i19–i30 (2008).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. North Am.10, 365–400 (1996).
   PubMed Web of Science ®Google Scholar
• Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert. Rev. Anti Infect. Ther.7(8), 981–988 (2009).
   PubMed Web of Science ®Google Scholar
• Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin. Investig. Drugs.18(9), 1279–1295 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect.10(Suppl. 1), 48–66 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al.In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol.46(8), 2568–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia170(5), 291–313 (2010).
   PubMed Web of Science ®Google Scholar
• Odds FC. Drug evaluation: BAL-8557, a novel broad-spectrum triazole antifungal. Curr. Opin. Investig. Drugs.7, 766–772 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffman A, Roos B, Roehrle M et al. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. Presented at: 48th Annual International Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, 25–28 October 2008.
   Google Scholar
• Schmitt-Hoffmann A, Roos B, Maares J et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother.50(1), 286–293 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickermann J et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob. Agents Chemother.53(11), 4885–4890 (2009).
   PubMed Web of Science ®Google Scholar
• Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium and Scedosporium species. Antimicrob. Agents Chemother.52(4), 1396–1400 (2008).
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Inagaki Y, Fujii T et al.In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int. J. Antimicrob. Agents.36(4), 324–331 (2010).
   PubMed Web of Science ®Google Scholar
• Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother.51(5), 1818–1821 (2007).
   PubMed Web of Science ®Google Scholar
• Mouton JW, Verweij PE, Warn P et al.In vitro activity of a new triazole BAL4815 against Candida isolates with decreased fluconazole susceptibility. Presented at: Trends in Medical Mycology (TIMM). Berlin, Germany, 23–26 October 2005.
   Google Scholar
• Sanglard D, Ischer F, Coste A, Rerrari S. Comparison between isavuconazole (ISA) and other azoles against characterized clinical isolates and yeast model systems. Presented at: 18th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19–22 April 2008.
   Google Scholar
• Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother.53(1), 309–311 (2009).
   PubMed Web of Science ®Google Scholar
• Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother.52(4), 1580–1582 (2008).
   PubMed Web of Science ®Google Scholar
• Guinea J, Hagen F, Peláez T et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med. Mycol.48(7), 942–948 (2010).
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother.57, 135–138 (2006).
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Lechner V, Lass-Flörl C; European Committee on Antimicrobial Susceptibility Testing. In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility testing. Antimicrob. Agents Chemother.53(4), 1645–1647 (2009).
   PubMed Web of Science ®Google Scholar
• Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med. Mycol.47, 71–76 (2009).
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Isham N. Antifungal activity of BAL4815, a novel azole, against dermatophytes. Presented at: Trends in Medical Mycology (TIMM). Berlin, Germany, 23–26 October 2005.
   Google Scholar
• Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother.45(7), 2151–2153 (2001).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia150, 101–115 (2001).
   PubMed Web of Science ®Google Scholar
• Guinea J, Recio S, Escribano P, Peláez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob. Agents Chemother.54, 4012–4015 (2010).
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, impact of immune status on antifungal effect. Antimicrob. Agents Chemother.53, 3453–3461 (2009).
   PubMed Web of Science ®Google Scholar
• Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic models of disseminated Candida tropicalis and Candida krusei. J. Antimicrob. Chemother.61, 161–166 (2009).
   Google Scholar
• Warn PA, Sharp A, Mosquera J et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother.58, 1198–1207 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M et al. Single ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother.50, 279–285 (2006).
   PubMed Web of Science ®Google Scholar
• Viljoen JJ, Mitha I, Heep M et al. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December 2005.
   Google Scholar
• Schmitt-Hoffman A, Roos B, Sauer J et al. Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 (WSA) and rifampicin. Presented at: 16th Congress of the International Society for Human and Animal Mycology (ISHAM). Paris, France, 25–26 June 2006.
   Google Scholar
• Schmitt-Hoffman A, Roos B, Sauer J et al. Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of Sand R-warfarin. Presented at: 16th Congress of the International Society for Human and Animal Mycology (ISHAM). Paris, France, 25–26 June 2006.
   Google Scholar
• Schmitt-Hoffman A, Roos B, Sauer J et al. Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of ciclosporin. Presented at: 16th Congress of the International Society for Human and Animal Mycology (ISHAM). Paris, France, 25–26 June 2006.
   Google Scholar
• Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J. Clin. Microbiol.44(5), 1782–1787 (2006).
   PubMed Web of Science ®Google Scholar
• González GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J. Clin. Microbiol.46(9), 2902–2905 (2008).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother.46(6), 1723–1727 (2002).
   PubMed Web of Science ®Google Scholar
• St-Germain G, Laverdière M, Pelletier R et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. M. Can. J. Infect. Dis. Med. Microbiol.19(1), 55–62 (2008).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro susceptibilities of rare Candida blood stream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis.48(2), 101–195 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol.43(5), 2163–2167 (2005).
   PubMed Web of Science ®Google Scholar
• Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother.44(10), 2883–2886 (2000).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol.41(8), 3623–3626 (2003).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother.46(4), 1032–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect.9(12), 1250–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob. Agents Chemother.49(12), 5136–5138 (2005).
   PubMed Web of Science ®Google Scholar
• Ortoneda M, Capilla J, Javier Pastor F et al.In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn. Microbiol. Infect. Dis.48, 69–71 (2004).
   PubMed Web of Science ®Google Scholar
• González GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol.43(3), 281–284 (2005).
   PubMed Web of Science ®Google Scholar
• Howard SJ, Webster I, Moore CB et al. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents.28(5), 450–453 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol.42(7), 3137–3141 (2004).
   PubMed Web of Science ®Google Scholar
• Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother.40(10), 2243–2247 (1996).
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob. Agents Chemother.45(12), 3433–3436 (2001).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J. Antimicrob. Chemother.49(2), 353–357 (2002).
   PubMed Web of Science ®Google Scholar
• Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother.44(12), 3381–3388 (2000).
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Lyman CA et al. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother.48(4), 1188–1196 (2004).
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Sarafandi A et al. Synergistic activity between ravuconazole and the echinocandin micafungin in treatment of experimental pulmonary aspergillosis. Presented at: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 27–30 September 2002.
   Google Scholar
• Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis.194, 1008–1118 (2006).
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother.47(4), 1193–1199 (2003).
   PubMed Web of Science ®Google Scholar
• Clemons KV, Martinez M, Calderon L, Stevens DA. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob. Agents Chemother.46(3), 922–924 (2002).
   PubMed Web of Science ®Google Scholar
• Olsen SJ, Mummaneni V, Rolan P et al. Ravuconazole single ascending oral dose study in healthy subjects. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17–20 September 2000.
   Google Scholar
• Grasela DM, Olsen SJ, Mummaneni V et al. Ravuconazole: multiple ascending oral dose study in healthy subjects. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17–20 September 2000.
   Google Scholar
• Bello A, Russo R, Grasela D et al. Pharmacokinetics of intravenous BMS-379224 (pro-drug of ravuconazole) in healthy male subjects. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14–17 September 2003.
   Google Scholar
• Marino MR, Mummanei V, Norton J et al. Ravuconazole exposure-response relationship in HIV-patients with oropharyngeal candidiasis. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16–19 December 2001.
   Google Scholar
• Beale M, Queiroz-Telles F, Banhegyi D et al. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 16–19 September 2001.
   Google Scholar
• Yan JH, Marino MR, Smith RA, Kanamaluru V, O’Mara EM, Grasela DM. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J. Clin. Pharmacol.46(2), 193–200 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Leonardi C, Stoltz RR, Pierce PF. A Phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol.19, 437–443 (2005).
   Web of Science ®Google Scholar
• Lin P, Mickiene D, Roden MM et al. Pharmacokinetics and safety of ravuconazole for prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA (2005) (Abstract A-220).
   Google Scholar
• Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents.21(1), 27–38 (2003).
   PubMed Web of Science ®Google Scholar
• Ramos G, Cuenca-Estrella M, Monzón A, Rodríguez-Tudela JL. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother.44, 283–286 (1999).
   PubMed Web of Science ®Google Scholar
• Miller JL, Schell WA, Wills EA et al.In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother.48, 384–387 (2004).
   PubMed Web of Science ®Google Scholar
• Morera-López Y, Torres-Rodríguez JM, Jiménez-Cabello T, Baró-Tomás T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol.43(6), 505–510 (2005).
   PubMed Web of Science ®Google Scholar
• Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother.45, 2635–2637 (2001).
   PubMed Web of Science ®Google Scholar
• Gilgado F, Serena C, Cano J, Gene J, Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob. Agents Chemother.50, 4211–4213 (2006).
   PubMed Web of Science ®Google Scholar
• Serena C, Ortoneda M, Capilla J et al.In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob. Agents Chemother.47(10), 3161–3164 (2003).
   PubMed Web of Science ®Google Scholar
• Garau M, Pereiro M Jr, del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob. Agents Chemother.47, 2342–2344 (2003).
   PubMed Web of Science ®Google Scholar
• Urbina JA, Lira R, Visbal G et al.In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother.44, 2498–2502 (2000).
   PubMed Web of Science ®Google Scholar
• Vericat ML, Algueró M, Merlos M, Pérez LL, Araño A, Forn J. UR-9825, a novel broad spectrum triazole for treatment of fungal infections: oral activity in systemic mycoses. In: Final Programme and Abstract Book Trends in Invasive Fungal Infections 4., Barcelona, Spain. Imedex, The Netherlands (1997) (Abstract P-94).
   Google Scholar
• González GM, Robledo E, Garza-González E, Elizondo M, González JG. Efficacy of albaconazole against Candida albicans in a vaginitis model. Antimicrob. Agents Chemother.53, 4540–4541 (2009).
   PubMed Web of Science ®Google Scholar
• Bartroli J, Turmo E, Alguero M et al. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted- 4(3H)-quinazolinones. J. Med. Chem.41, 1869–1882 (1998).
   PubMed Web of Science ®Google Scholar
• Guedes PM, Urbina JA, de Lana M et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother.48(11), 4286–4292 (2004).
   PubMed Web of Science ®Google Scholar
• Capilla J, Yustes C, Mayayo E et al. Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob. Agents Chemother.47, 1948–1951 (2003).
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Lurigados C, Perez I et al. First administration into man of UR-9825: a new triazole class of antifungal agent. In: Abstracts of the Sixth Congress of the European Confederation of Medical Mycology Societies (ECMM). Barcelona, Spain (2000) (Abstract P2-004).
   Google Scholar
• Bartroli X, Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicriobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA (2005) (Abstract M-722).
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet362, 1142–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Lowther J et al.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother.47, 1187–1192 (2003).
   PubMed Web of Science ®Google Scholar
• Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J. Clin. Microbiol.44, 4342–4344 (2006).
   PubMed Web of Science ®Google Scholar
• Laverdiere M, Labbé AC, Restieri C et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J. Crit. Care22, 245–250 (2007).
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Dutta S, Isham N. The effect of aminocandin compared to caspofungin and micafungin. In: Abstracts of the Sixteenth European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (2006) (Abstract P-746).
   Google Scholar
• Warn PA, Sharp A, Morrissey G et al. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole resistant strain of Candida tropicalis. J. Antimicrob. Chemother.56, 590–593 (2005).
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Kim HG, Long L. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis. J. Antimicrob. Chemother.59, 556–559 (2007).
   PubMed Web of Science ®Google Scholar
• Brzankalski GE, Najvar LK, Wiederhold NP et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J. Antimicrob. Chemother.62, 1094–1100 (2008).
   PubMed Web of Science ®Google Scholar
• Najvar LK, Bocanegra R, Wiederhold NP et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin. Microbiol. Infect.4, 595–600 (2008).
   Google Scholar
• Warn PA, Sharp A, Morrissey G, Denning DW. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. Int. J. Antimicrob. Agents.35, 146–151 (2010).
   PubMed Web of Science ®Google Scholar
• Sandage B, Cooper G, Najarian N et al. Pharmacokinetics and fungicidal activity of aminocandin (HMR3270), a novel echinocandin in healthy volunteers. In: Abstracts of the Fifteenth European Congress of Clinical Microbiology and Infectious Diseases. European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (2005) (Abstract P-1115).
   Google Scholar
• Kakeya H, Miyazaki Y, Senda H et al. Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis. Antimicrob. Agents Chemother.52(5), 1871–1872 (2008).
   PubMed Web of Science ®Google Scholar
• Rimaroli C, Bruzzese T. In vitro activity of a new polyene, SPA-S-843, against yeasts. Antimicrob. Agents Chemother.42(11), 3012–3013 (1998).
   PubMed Web of Science ®Google Scholar
• Kakeya H, Miyazaki Y, Senda H et al. Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrob. Agents Chemother.52, 1868–1870 (2008).
   PubMed Web of Science ®Google Scholar
• Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemother.48, 3968–3974 (2004).
   PubMed Web of Science ®Google Scholar
• Mitsuyama J, Nomura N, Hashimoto K et al.In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob. Agents Chemother.52(4), 1318–1324 (2008).
   PubMed Web of Science ®Google Scholar
• Hasenoehrl A, Galic T, Ergovic G et al.In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob. Agents Chemother.50(9), 3011–3018 (2006).
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Kelaher AM et al. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother.49(5), 2084–2092 (2005).
   PubMed Web of Science ®Google Scholar
• Kitamura A, Someya K, Hata M, Nakajima R, Takemura M. Discovery of a small-molecule inhibitor of {β}-1,6-glucan synthesis. Antimicrob. Agents Chemother.53(2), 670–677 (2009).
   PubMed Web of Science ®Google Scholar